<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Identification and reversal of treatment resistance mechanisms of clinically <z:e sem="disease" ids="C1335729" disease_type="Neoplastic Process" abbrv="">refractory tumor</z:e> cells is critical for successful <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that ATP-binding cassette member B5 (ABCB5) identifies therapy-<z:e sem="disease" ids="C1335729" disease_type="Neoplastic Process" abbrv="">refractory tumor</z:e> cells in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients following fluorouracil (5-FU)-based <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy and provide evidence for a functional role of ABCB5 in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> 5-FU resistance </plain></SENT>
<SENT sid="2" pm="."><plain>Examination of human colon and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> specimens revealed ABCB5 to be expressed only on rare cells within healthy intestinal tissue, whereas clinical <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> exhibited substantially increased levels of ABCB5 expression </plain></SENT>
<SENT sid="3" pm="."><plain>Analysis of successive, patient-matched biopsy specimens obtained prior to and following neoadjuvant 5-FU-based <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy in a series of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients revealed markedly enhanced abundance of ABCB5-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells when <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> was detected </plain></SENT>
<SENT sid="4" pm="."><plain>Consistent with this finding, the ABCB5-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell population was also treatment refractory and exhibited resistance to 5-FU-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> of 5-FU monotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Mechanistically, short hairpin <z:chebi fb="40" ids="33697">RNA</z:chebi>-mediated ABCB5 knockdown significantly inhibited tumorigenic xenograft growth and sensitized <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells to 5-FU-induced cell killing </plain></SENT>
<SENT sid="6" pm="."><plain>Our results identify ABCB5 as a novel molecular marker of therapy-<z:e sem="disease" ids="C1335729" disease_type="Neoplastic Process" abbrv="">refractory tumor</z:e> cells in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients and point to a need for consistent eradication of ABCB5-positive resistant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell populations for more effective <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> therapy </plain></SENT>
</text></document>